Clinical outcomes of monoclonal antibody therapy during a COVID-19 outbreak in a skilled nursing facility-Arizona, 2021.
Ariella Perry DaleMatthew J HudsonDarunee ArmentaHeather FriebusKatherine D EllingsonKat DavisTheresa CullenShane BradyKenneth K KomatsuNimalie D StoneTimothy M UyekiKara Jacobs SlifkaCarlos M Pérez-VélezAmelia A KeatonPublished in: Journal of the American Geriatrics Society (2022)
mAb therapy was successfully administered to SNF residents with COVID-19 in a large outbreak setting. Treatment with bamlanivimab reduced 21-day mortality and reduced initiation of oxygen therapy. As the COVID-19 pandemic evolves and newer immunotherapies gain FDA authorization, more studies of the effectiveness of mAb therapies for treating emerging SARS-CoV-2 variants of concern in high-risk congregate settings are needed.